{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:14:12Z","timestamp":1789384452573,"version":"build-2803163510"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T00:00:00Z","timestamp":1374451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\u2003<\/jats:title>\n                    <jats:p>Atherosclerosis and osteoporosis are chronic diseases that progress with age, and studies suggest aortic calcification, an indicator of atherosclerosis, is inversely associated with bone mineral density (BMD). The osteoprotegerin (OPG)\/receptor activator of NF-\u03baB (RANK)\/RANK ligand (RANKL) system has been proposed as a shared regulatory system for bone and vasculature. Denosumab (DMAb), a monoclonal antibody against RANKL, improved BMD and reduced fracture risk in the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. We evaluated whether or not treatment with DMAb influenced progression of aortic calcification (AC) and incidence of cardiovascular (CV) adverse events. We included 2363 postmenopausal women with osteoporosis (1142 placebo, 1221 DMAb), selected from 7808 participants in the FREEDOM trial (3906 placebo, 3902 DMAb), at high risk of CV events according to modified Raloxifene Use for the Heart (RUTH) criteria. CV adverse events were reported by participants. AC scores were assessed using a semiquantitative method from lateral spine X-rays. Change in AC score from baseline to 12 (n\u2009=\u20091377), 24 (n\u2009=\u20091231), and 36 months (n\u2009=\u20091045) was calculated as AC score at follow-up minus AC score at baseline. AC progression was defined as change in AC score &amp;gt;0. Baseline characteristics, CV risk factors, and AC scores were similar between treatment groups. Mean age of participants was 74 years (range, 60\u201390), 88% were white, and 77% had AC score &amp;gt;0 at baseline. Frequency of AC progression over 3 years did not differ between women in placebo (22%) and DMAb (22%) groups (p\u2009=\u20090.98). AC progression did not differ between treatment groups when analyzed by baseline estimated glomerular filtration rate or by baseline AC scores. Frequency of CV adverse events did not differ between placebo (40%) and DMAb (38%) groups (p\u2009=\u20090.26). In conclusion, DMAb treatment had no effect on progression of AC or incidence of CV adverse events compared to placebo. \u00a9 2014 American Society for Bone and Mineral Research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jbmr.2043","type":"journal-article","created":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T01:52:37Z","timestamp":1374457957000},"page":"450-457","source":"Crossref","is-referenced-by-count":119,"title":["RANKL Inhibition With Denosumab Does Not Influence 3-Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk"],"prefix":"10.1093","volume":"29","author":[{"given":"Elizabeth J","family":"Samelson","sequence":"first","affiliation":[{"name":"Institute for Aging ResearchHebrew Senior Life and Harvard Medical SchoolBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D","family":"Miller","sequence":"additional","affiliation":[{"name":"Colorado Center for Bone ResearchLakewoodCOUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Christiansen","sequence":"additional","affiliation":[{"name":"Center for Clinical and Basic ResearchBallenrupDenmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia S","family":"Daizadeh","sequence":"additional","affiliation":[{"name":"Amgen Inc.Thousand OaksCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luanda","family":"Grazette","sequence":"additional","affiliation":[{"name":"Keck Medical Center of University of Southern CaliforniaLos AngelesCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary S","family":"Anthony","sequence":"additional","affiliation":[{"name":"Amgen Inc.Thousand OaksCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogo","family":"Egbuna","sequence":"additional","affiliation":[{"name":"Amgen Inc.Thousand OaksCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wang","sequence":"additional","affiliation":[{"name":"Amgen Inc.Thousand OaksCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh R","family":"Siddhanti","sequence":"additional","affiliation":[{"name":"Amgen Inc.Thousand OaksCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M","family":"Cheung","sequence":"additional","affiliation":[{"name":"University Health Network and University of TorontoTorontoONCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Franchimont","sequence":"additional","affiliation":[{"name":"Biogen IdecCambridgeMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas P","family":"Kiel","sequence":"additional","affiliation":[{"name":"Institute for Aging ResearchHebrew Senior Life and Harvard Medical SchoolBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,7,22]]},"reference":[{"issue":"11","key":"2024020318571289100_jbmr2043-bib-0001","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1161\/01.CIR.103.11.1529","article-title":"Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality","volume":"103","author":"Wilson","year":"2001","journal-title":"Circulation."},{"issue":"5","key":"2024020318571289100_jbmr2043-bib-0002","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF02390833","article-title":"Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study","volume":"68","author":"Kiel","year":"2001","journal-title":"Calcif Tissue Int."},{"issue":"8","key":"2024020318571289100_jbmr2043-bib-0003","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00198-007-0539-1","article-title":"Progression of vascular calcifications is associated with greater bone loss and increased bone fractures","volume":"19","author":"Naves","year":"2008","journal-title":"Osteoporos Int."},{"issue":"8","key":"2024020318571289100_jbmr2043-bib-0004","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1161\/01.ATV.20.8.1926","article-title":"Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study","volume":"20","author":"Hak","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"6","key":"2024020318571289100_jbmr2043-bib-0005","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2796.2006.01640.x","article-title":"Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip","volume":"259","author":"Bagger","year":"2006","journal-title":"J Intern Med."},{"issue":"1","key":"2024020318571289100_jbmr2043-bib-0006","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2796.2004.01430.x","article-title":"French women, fractures and aortic calcifications","volume":"257","author":"Rajzbaum","year":"2005","journal-title":"J Intern Med."},{"issue":"1","key":"2024020318571289100_jbmr2043-bib-0007","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1359\/jbmr.070903","article-title":"Calcifications in the abdominal aorta predict fractures in men: MINOS study","volume":"23","author":"Szulc","year":"2008","journal-title":"J Bone Miner Res."},{"issue":"9","key":"2024020318571289100_jbmr2043-bib-0008","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1210\/jc.2003-030964","article-title":"Aortic calcification and the risk of osteoporosis and fractures","volume":"89","author":"Schulz","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2024020318571289100_jbmr2043-bib-0009","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1359\/jbmr.060903","article-title":"Volumetric BMD and vascular calcification in middle-aged women: the Study of Women's Health Across the Nation","volume":"21","author":"Farhat","year":"2006","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024020318571289100_jbmr2043-bib-0010","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/aje\/kwn303","article-title":"Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study","volume":"169","author":"Hyder","year":"2009","journal-title":"Am J Epidemiol."},{"key":"2024020318571289100_jbmr2043-bib-0011","doi-asserted-by":"crossref","first-page":"748380","DOI":"10.4061\/2010\/748380","article-title":"A radiographic study on the associations of age and prevalence of vertebral fractures with abdominal aortic calcification in Japanese postmenopausal women and men","volume":"2010","author":"Iwamoto","year":"2010","journal-title":"J Osteoporos."},{"issue":"3","key":"2024020318571289100_jbmr2043-bib-0012","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00198-006-0282-z","article-title":"Vascular calcification and osteoporosis--from clinical observation towards molecular understanding","volume":"18","author":"Hofbauer","year":"2007","journal-title":"Osteoporos Int."},{"issue":"2","key":"2024020318571289100_jbmr2043-bib-0013","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell."},{"issue":"2","key":"2024020318571289100_jbmr2043-bib-0014","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell."},{"issue":"6","key":"2024020318571289100_jbmr2043-bib-0015","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.coph.2005.06.005","article-title":"Osteoprotegerin and RANKL regulate bone resorption, density, g eometry and strength","volume":"5","author":"Kostenuik","year":"2005","journal-title":"Curr Opin Pharmacol."},{"issue":"8","key":"2024020318571289100_jbmr2043-bib-0016","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"issue":"6","key":"2024020318571289100_jbmr2043-bib-0017","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1586\/14779072.4.6.801","article-title":"The osteoprotegerin\/RANK\/RANKL system: a bone key to vascular disease","volume":"4","author":"Kiechl","year":"2006","journal-title":"Expert Rev Cardiovasc Ther."},{"issue":"4","key":"2024020318571289100_jbmr2043-bib-0018","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/01.ATV.0000012303.37971.DA","article-title":"RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function","volume":"22","author":"Schoppet","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"2","key":"2024020318571289100_jbmr2043-bib-0019","first-page":"631","article-title":"Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women","volume":"86","author":"Browner","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2024020318571289100_jbmr2043-bib-0020","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev."},{"issue":"4","key":"2024020318571289100_jbmr2043-bib-0021","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1084\/jem.192.4.463","article-title":"Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis","volume":"192","author":"Min","year":"2000","journal-title":"J Exp Med."},{"issue":"3","key":"2024020318571289100_jbmr2043-bib-0022","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/CIRCULATIONAHA.107.707380","article-title":"Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-\/-) mice","volume":"117","author":"Morony","year":"2008","journal-title":"Circulation."},{"issue":"9","key":"2024020318571289100_jbmr2043-bib-0023","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1161\/01.ATV.0000236428.91125.e6","article-title":"Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-\/- mice","volume":"26","author":"Bennett","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"10","key":"2024020318571289100_jbmr2043-bib-0024","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1161\/hq1001.097102","article-title":"Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D","volume":"21","author":"Price","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"10","key":"2024020318571289100_jbmr2043-bib-0025","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/01.CIR.0000031524.49139.29","article-title":"Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease","volume":"106","author":"Jono","year":"2002","journal-title":"Circulation."},{"issue":"1","key":"2024020318571289100_jbmr2043-bib-0026","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1530\/eje.0.1490039","article-title":"Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications","volume":"149","author":"Knudsen","year":"2003","journal-title":"Eur J Endocrinol."},{"issue":"18","key":"2024020318571289100_jbmr2043-bib-0027","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/01.CIR.0000127957.43874.BB","article-title":"Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease","volume":"109","author":"Kiechl","year":"2004","journal-title":"Circulation."},{"issue":"6","key":"2024020318571289100_jbmr2043-bib-0028","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2215\/CJN.11191111","article-title":"Osteoprotegerin\/RANKL axis and progression of coronary artery calcification in hemodialysis patients","volume":"7","author":"Ozkok","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"2024020318571289100_jbmr2043-bib-0029","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1161\/01.CIR.0000060815.25798.02","article-title":"Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men","volume":"107","author":"Schoppet","year":"2003","journal-title":"Circulation."},{"issue":"4","key":"2024020318571289100_jbmr2043-bib-0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/CIRCULATIONAHA.106.686774","article-title":"Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease","volume":"116","author":"Kiechl","year":"2007","journal-title":"Circulation."},{"issue":"4","key":"2024020318571289100_jbmr2043-bib-0031","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0002-9149(01)01685-X","article-title":"Design and methods of the Raloxifene Use for The Heart (RUTH) study","volume":"88","author":"Mosca","year":"2001","journal-title":"Am J Cardiol."},{"issue":"1","key":"2024020318571289100_jbmr2043-bib-0032","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1185\/030079904X18045","article-title":"Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial","volume":"21","author":"Keech","year":"2005","journal-title":"Curr Med Res Opin."},{"issue":"2","key":"2024020318571289100_jbmr2043-bib-0033","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0021-9150(97)00106-8","article-title":"New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study","volume":"132","author":"Kauppila","year":"1997","journal-title":"Atherosclerosis."},{"issue":"8","key":"2024020318571289100_jbmr2043-bib-0034","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024020318571289100_jbmr2043-bib-0035","first-page":"98","article-title":"Comparison of estimated creatinine clearance among five formulae (Cockroft-Gault, Jelliffe, Sanaka, simplified 4-variable MDRD and DAF) and the 24hours-urine-collection creatinine clearance","volume":"14","author":"Diamandopoulos","year":"2010","journal-title":"Hippokratia."},{"issue":"3","key":"2024020318571289100_jbmr2043-bib-0036","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2004070549","article-title":"Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function","volume":"16","author":"Froissart","year":"2005","journal-title":"J Am Soc Nephrol."},{"issue":"18","key":"2024020318571289100_jbmr2043-bib-0037","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1001\/jama.2012.3954","article-title":"Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate","volume":"307","author":"Matsushita","year":"2012","journal-title":"JAMA."},{"issue":"11","key":"2024020318571289100_jbmr2043-bib-0038","doi-asserted-by":"crossref","first-page":"785","DOI":"10.7326\/0003-4819-156-11-201203200-00391","article-title":"Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review","volume":"156","author":"Earley","year":"2012","journal-title":"Ann Intern Med."},{"issue":"6","key":"2024020318571289100_jbmr2043-bib-0039","first-page":"797","article-title":"Evaluating the performance of equations for estimating glomerular filtration rate","volume":"21","author":"Stevens","year":"2008","journal-title":"J Nephrol."},{"issue":"12","key":"2024020318571289100_jbmr2043-bib-0040","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.2215\/CJN.04320709","article-title":"Coronary calcification in patients with chronic kidney disease and coronary artery disease","volume":"4","author":"Nakamura","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"issue":"13","key":"2024020318571289100_jbmr2043-bib-0041","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med."},{"issue":"1","key":"2024020318571289100_jbmr2043-bib-0042","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/CIRCULATIONAHA.106.678342","article-title":"Chronic kidney disease: effects on the cardiovascular system","volume":"116","author":"Schiffrin","year":"2007","journal-title":"Circulation."},{"issue":"2","key":"2024020318571289100_jbmr2043-bib-0043","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s00198-004-1662-x","article-title":"Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women","volume":"16","author":"Tank\u00f3","year":"2005","journal-title":"Osteoporosis Int."},{"key":"2024020318571289100_jbmr2043-bib-0044","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1681\/ASN.2006080925","article-title":"Vascular calcifications: pathogenesis, management, and impact on clinical outcomes","volume":"17","author":"Cannata-Andia","year":"2006","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"2024020318571289100_jbmr2043-bib-0045","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1359\/jbmr.080109","article-title":"RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats","volume":"23","author":"Ominsky","year":"2008","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024020318571289100_jbmr2043-bib-0046","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2353\/ajpath.2009.080957","article-title":"Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice","volume":"175","author":"Helas","year":"2009","journal-title":"Am J Pathol."},{"issue":"4","key":"2024020318571289100_jbmr2043-bib-0047","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1042\/CS20050058","article-title":"Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction","volume":"109","author":"Crisafulli","year":"2005","journal-title":"Clin Sci (Lond)."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2043","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/29\/2\/450\/56565861\/jbmr2043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/29\/2\/450\/56565861\/jbmr2043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:50:02Z","timestamp":1710327002000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/29\/2\/450-457\/7598961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,22]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,7,22]]},"published-print":{"date-parts":[[2014,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.2043","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,2,1]]},"published":{"date-parts":[[2013,7,22]]}}}